Platelet Preparation
Transfusion • Category : Platelet Preparation
Solution additive plaquettaire SSP+

SSP+ Platelet Additive Solution

The use of Platelet Additive Solution is a major step to improve transfusion safety thanks to a significant reduction of patient adverse reactions and ABO incompatibility.

Macopharma develops and manufactures solutions to improve the quality and the safety of platelets, allowing better patient outcome.

SSP+ Platelet Additive Solution is a substitute for plasma in preparation
and storage of buffy-coat (BC) and aphaeresis platelet concentrates (PCs)

The recommended ratio is 70% SSP+ 30% Plasma (possible ratio up to 80% SSP+ 20% Plasma).
Since 2004, more than 8 millions of Platelet concentrates have been stored in SSP+, across more than 40 countries (Data from 2020).


Platelet quality:
• More standardised platelet concentrates,
• Improved storage conditions (pH, HSR, Aggregation,…)

Plasma saving:
• Recovered additional plasma used for other purposes: additional therapeutic plasma available & additional income

Stock management improvement:
• Storage time can be extended up to 7 days (according to the law in force),
• Availability of platelets is improved over weekends and public holidays,
• The discard-rate can be reduced by decreasing the number of outdated platelet concentrates,
• Platelet concentrates can be stored up to 4 days without agitation.

Patient Safety

Implementing SSP+ avoids transfusion of large volumes of plasma, thus reducing the risk of plasma-related adverse transfusion reactions (TRALI),

Reduces the risk of adverse reactions due to ABO minor incompatibility,

No risk due to mismatching plasma for resuspension.


Different volumes available : 200mL, 220mL, 250mL, 280mL, 300mL, 500mL

2 connection modes available (for both manual & aphaeresis)

Barcode ISBT 128

Polyolefin bag (Non PVC)

Compatible with all techniques (manual and automatic)


• Reports of haemovigilance from several countries demonstrate a significant reduction in the rate of allergic events wih platelets suspended in PAS compared to platelets suspended in plasma.
• Platelet concentrates from Buffy-Coat in SSP+ additive solution show superior in vitro parameters when compared with those stored in plasma. (Storage of platelet concentrates -Present and future, P. Van der Meer.)
• Novel PAS containing glucose, calcium and bicarbonate does not seem to be associated with improved in vitro results as compared to SSP+ when PLTs are stored with 35% plasma inclusion. (Platelet storage media, H. Gulliksson.)
• HSR, regarded as one of the best single in vitro parameters to predict post-transfusion efficacy, is higher after 7-day storage in SSP+ as compared to Intersol. (in vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solution, B. Diedrich et al.)
• SSP+ is effective for both preserving the in vitro properties of PLTs and preventing accelerated glycolysis. (Parallel comparison of apheresis collected platelet concentrates stored in four different additive solutions, M. Nogawa et al.)
• Storage of PLTs in SSP+ improved the quality of PCs in terms of better maintained PLT count, lower glucose metabolism, lower spontaneous activation, and improved response to a PLT agonist compared to PLTs in T-Sol. (in vitro properties of platelets stored in three different additive solutions, N. Tynngard et al.)

Other products in Platelet Preparation
THROMBOFLEX Platelet leukoreduction filter

This information is for exclusive use of healthcare professionals.
The products are not available in every country, please contact your sales representative.
MACOPHARMA • Rue Lorthiois 59240 Mouvaux France • Tel : + 33 (0) 3 20 11 84 00 • Fax : +33 (0) 3 20 11 84 03
Société par actions simplifiée au Capital de 493.115 € RCS Lille Metropole 391 600 905 • Code APE 4641 Z • TVA FR 313 916 009 05